Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer

This study has been completed.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Hoosier Cancer Research Network Identifier:
First received: August 28, 2007
Last updated: May 14, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Chiorean EG, Picus J, Breen T, Ansari RH, Harb WA, Burns M, Spittler AJ, Loehrer PJ. Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. J Clin Oncol 33:5s, 2015 (suppl; abstr 3618)